IDEAYA Biosciences
IDYA · Nasdaq · United States
Share price · IDYA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IDYA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-9.7%
- 29 Oct 2026-3.2%
Nothing announced by IDYA that day or the session before.
- 26 Oct 2026-5.3%
- 22 Jun 2026+9.6%
Nothing announced by IDYA that day or the session before.
- 9 Jun 2026-10.8%
- 8 Jun 2026+11.3%
- 13 Apr 2026+7.6%
- 23 Mar 2026-3.4%
- 3 Mar 2026+3.8%
Nothing announced by IDYA that day or the session before.
- 19 Feb 2026+6.4%
Nothing announced by IDYA that day or the session before.
Share of unusual movement by asset
For each asset, the share of IDYA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Protein kinase C (PKC) (inhibitor)Small molecule | Uveal Melanoma | |
| Phase 1/2 | PARGSmall molecule | Ovarian Cancer | |
| Phase 1/2 | MAT2ASmall molecule | Non-Small Cell Lung CancerBladder Cancer | |
| Phase 1 | B7H3 and PTK7 (bispecific, co-expression-dependent internalization)Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1 | KAT6/KAT7Small molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | PRMT5Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
January 2027 (2)
What to watch
What to watch
April 2027 (1)
What to watch
2029 (1)
2030 (1)
October 2030 (1)
What to watch
2034 (1)
March 2034 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $10M | $122M | $263M+ $577M short-term inv. | $126M-$93M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $8.9M | $109M | $274M+ $556M short-term inv. | $112M-$88M operating cash flow | report ↗ |
| 2026-Q1 | $6.6M | $96M | $159M+ $514M short-term inv. | $99M-$75M operating cash flow | report ↗ |
| 2025-Q4 | — | $87M | $114M+ $527M short-term inv. | —-$91M operating cash flow | report ↗ |
| 2025-Q3 | $208M | $83M | $300M+ $488M short-term inv. | —$142M operating cash flow | report ↗ |
| 2025-Q2 | — | $74M | $115M+ $555M short-term inv. | $77M-$62M operating cash flow | report ↗ |
| 2025-Q1 | — | $71M | $131M+ $563M short-term inv. | $72M-$60M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $57M | $401M+ $520M short-term inv. | $52M-$49M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $55M | $184M+ $519M short-term inv. | $53M-$33M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $43M | $109M+ $590M short-term inv. | $40M-$44M operating cash flow | report ↗ |
| 2023-Q3 | $8.0M | $34M | $153M+ $317M short-term inv. | $27M-$30M operating cash flow | report ↗ |
| 2023-Q2 | $3.5M | $29M | $104M+ $391M short-term inv. | $28M-$33M operating cash flow | report ↗ |
| 2023-Q1 | $7.9M | $28M | $67M+ $272M short-term inv. | $24M-$28M operating cash flow | report ↗ |
| 2022-Q3 | $30M | $22M | $102M+ $284M short-term inv. | —-$24M operating cash flow | report ↗ |
| 2022-Q2 | $5.8M | $23M | $49M+ $220M short-term inv. | $22M-$20M operating cash flow | report ↗ |
| 2022-Q1 | $11M | $20M | $55M+ $197M short-term inv. | $14M-$20M operating cash flow | report ↗ |
| 2021-Q3 | $9.0M | $16M | $109M+ $156M short-term inv. | $12M-$12M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $219M | $315M | $114M+ $527M short-term inv. | $28M-$71M operating cash flow | report ↗ |
For FY2025, IDEAYA reported collaboration revenue of $218.71M, up 3024.4% YoY, with R&D expenses of $314.7M, up 6.8% YoY. The company ended the year with approximately $1.05 billion in cash, cash equivalents and marketable securities, and recorded a net loss of $113.7M, compared with a $274.5M net loss in 2024.
Topline PFS results from the Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib in 1L HLA*A2-negative metastatic uveal melanoma are expected by approximately the last week of March, with 130 PFS events confirmed by BICR. Darovasertib is anticipated to enter three randomized Phase 3 trials across uveal melanoma settings by H1 '26, and IDE849 registrational study initiation with preliminary Phase 1 data is targeted for end of 2026. GSK notified IDEAYA of termination of the Werner Helicase and Pol Theta collaboration, with program transfer back to IDEAYA, while the company received a $210.0M upfront payment from Servier during 2025. Cash is expected to fund operations into 2030.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $7.0M | $295M | $85M+ $592M short-term inv. | $69M-$248M operating cash flow | report ↗ |
| 2023-FY | $23M | $130M | $158M+ $368M short-term inv. | $28M-$115M operating cash flow | report ↗ |
| 2022-FY | $51M | $90M | $69M+ $296M short-term inv. | $15M-$87M operating cash flow | report ↗ |
| 2021-FY | $28M | $58M | $92M+ $155M short-term inv. | $12M-$56M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($1.6M), 3 sales ($1.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-06 | Hata Yujiro S · director, President and CEO | Option exercise | 26,338 | $4.31 | $114K | Form 4 |
| 2026-10-06 | Hata Yujiro S · director, President and CEO | Open-market sale | 25,538 | $37.39 | $955K | Form 4 |
| 2026-10-06 | Hata Yujiro S · director, President and CEO | Open-market sale | 800 | $38.26 | $31K | Form 4 |
| 2026-10-06 | Hata Yujiro S · director, President and CEO | Option exercise (derivative) | 26,338 | — | — | Form 4 |
| 2026-07-07 | Ruiz Briseno Andres · Chief Accounting Officer | Option exercise | 9,550 | $12.86 | $123K | Form 4 |
| 2026-07-07 | Ruiz Briseno Andres · Chief Accounting Officer | Open-market sale | 9,550 | $40.01 | $382K | Form 4 |
| 2026-07-07 | Ruiz Briseno Andres · Chief Accounting Officer | Option exercise (derivative) | 9,550 | — | — | Form 4 |
| 2026-06-16 | Hampton Malcolm Garret · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 252 reporting institutions held 94.7M shares ($3.1B, 97.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 13,172,103 | $438.9M |
| 2 | BlackRock, Inc. | 8,442,133 | $281.3M |
| 3 | JANUS HENDERSON GROUP PLC | 7,265,253 | $242.0M |
| 4 | Capital Research Global Investors | 5,163,543 | $172.0M |
| 5 | BAKER BROS. ADVISORS LP | 3,946,515 | $131.5M |
| 6 | STATE STREET CORP | 3,781,167 | $126.0M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3,732,422 | $124.4M |
| 8 | Logos Global Management LP | 3,450,000 | $115.0M |
| 9 | FEDERATED HERMES, INC. | 2,987,107 | $99.5M |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,823,500 | $94.1M |
| 11 | Fiera Capital Corp | 2,527,076 | $84.2M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 2,500,724 | $83.3M |
| 13 | MORGAN STANLEY | 1,860,453 | $62.0M |
| 14 | GOLDMAN SACHS GROUP INC | 1,655,617 | $55.2M |
| 15 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1,530,008 | $51.0M |